Journal
GENES
Volume 12, Issue 4, Pages -Publisher
MDPI
DOI: 10.3390/genes12040507
Keywords
variant calling; performance validation; liquid biopsy; NGS; precision medicine; early cancer detection
Categories
Funding
- Quantgene Inc., (Santa Monica, CA, USA)
Ask authors/readers for more resources
DEEPGEN(TM) is a variant calling assay intended for the detection of low frequency variants within liquid biopsy samples, with demonstrated effectiveness in discriminating between signal and noise and superior sensitivity.
Detection of genetic variants in clinically relevant genomic hot-spot regions has become a promising application of next-generation sequencing technology in precision oncology. Effective personalized diagnostics requires the detection of variants with often very low frequencies. This can be achieved by targeted, short-read sequencing that provides high sequencing depths. However, rare genetic variants can contain crucial information for early cancer detection and subsequent treatment success, an inevitable level of background noise usually limits the accuracy of low frequency variant calling assays. To address this challenge, we developed DEEPGEN(TM), a variant calling assay intended for the detection of low frequency variants within liquid biopsy samples. We processed reference samples with validated mutations of known frequencies (0%-0.5%) to determine DEEPGEN(TM)'s performance and minimal input requirements. Our findings confirm DEEPGEN(TM)'s effectiveness in discriminating between signal and noise down to 0.09% variant allele frequency and an LOD(90) at 0.18%. A superior sensitivity was also confirmed by orthogonal comparison to a commercially available liquid biopsy-based assay for cancer detection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available